BioSpace News Archive

GE HealthCare is presenting three new global innovations – Intelligent Radiation Therapy, Auto Segmentation, and an updated Magnetic Resonance Radiation Therapy Suite – that underscore the company’s commitment to enhancing the radiation oncology care pathway.

Novarad’s VisAR, a surgical navigation system that uses augmented reality, has received clearance from Indonesia’s FDA for intraoperative use in stereotactic spinal surgery.

Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

LaNova Medicines Ltd. (“LaNova Medicines”) announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1 on May 12.

Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.

InspireMD, Inc. announced that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open.

Jasper Therapeutics, Inc. announced results for the fiscal quarter ended March 31, 2023, and provided a business update.